# A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer

> **NCT00855894** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 41 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Pertuzumab
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00855894
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2013-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00855894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00855894, "A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00855894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*